INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

Impact · against what's priced in

PepGen faces significant headwinds following a partial FDA clinical hold on its PGN-EDODM1 trial and subsequent securities fraud investigation. While the clinical hold was announced on March 4, the current law firm investigation adds a layer of legal and financial risk. AWI and ADMA are also subject to separate investigations by the same law firm, introducing new potential legal liabilities.

PEPG−0.80

No priced-in read yet